Abstract
Background: Breast milk is a vehicle to transfer protective antibodies from the lactating mother to the neonate. After SARS-CoV-2 infection, virus-specific IgA and IgG have been identified in breast milk, however, there are limited data on the impact of different COVID-19 vaccine types in lactating women. This study is aimed to evaluate the time course of induction of SARS-CoV-2-specific IgA and IgG in breast milk after vaccination.
Methods: In this prospective observational study in Spain, 86 lactating women from priority groups receiving the vaccination against SARS-CoV-2 were included. Breast milk samples were collected longitudinally at seven or eight-time points (depending on vaccine type). A group with confirmed SARS-CoV-2 infection (n=19) and a group of women from pre-pandemic time (n=20) were included for comparison.
Results: Eighty-six vaccinated lactating women [mean age, 34.6 ± 3.7 years] of whom 96% were Caucasian and 92% were healthcare workers. A total number of 582 milk samples were included, and vaccine distribution was BioNTech/Pfizer (BNT162b2, n=34), Moderna (mRNA-1273, n=20), and AstraZeneca (ChAdOx1 nCoV-19, n=32). For each vaccine, 7 and 8 longitudinal time points were collected from baseline up to 30 days after the second dose for mRNA vaccines and adenovirus-vectored vaccines, respectively. A strong reactivity was observed for IgG and IgA after vaccination mainly after the 2 nd dose. The presence and persistence of specific SARS-CoV-2 antibodies in breast milk were dependent on the vaccine type, with higher IgG and IgA levels in mRNA-based vaccines when compared to AstraZeneca, and on previous virus exposure. High intra- and inter-variability were observed, being relevant for IgA antibodies. In milk from vaccinated women, anti-SARS-CoV-2 IgG was significantly higher while IgA levels were lower than in milk from COVID-19-infected women. Women with previous COVID-19 increased their IgG antibodies levels after the first dose to a similar level observed in vaccinated women after the second dose.
Conclusions: COVID-19 vaccination induced anti-SARS-CoV-2 IgA and IgG in breast milk with higher levels after the 2 nd dose. Levels of anti-SARS-CoV-2 IgA and IgG are dependent on the vaccine type. Further studies are warranted to demonstrate the protective antibody effect against COVID-19 in infants from vaccinated and infected mothers.
Trial registration: NCT04751734 (date of registration is on February 12, 2021).
Keywords: Antibodies; Breast milk; Immunoglobulins; SARS-CoV-2; Vaccines.
【저자키워드】 antibodies, SARS-CoV-2, immunoglobulins, Vaccines., breast milk, 【초록키워드】 COVID-19, IgG, Vaccine, COVID-19 vaccine, vaccination, Vaccines, antibody, mRNA vaccine, mRNA-1273, prospective observational study, SARS-COV-2 infection, virus, anti-SARS-CoV-2, Infant, BNT162b2, IgG antibody, Breast, SARS-CoV-2 antibody, COVID-19 vaccination, anti-SARS-CoV-2 IgG, IgA, persistence, healthcare, Spain, age, women, group, distribution, AstraZeneca, ChAdOx1 nCoV-19, Moderna, Protective, Protective antibody, mother, dose, second dose, first dose, IgA antibodies, transfer, mRNA-based vaccine, lactating women, Seven, Course, collected, evaluate, receiving, dependent on, significantly higher, reactivity, the vaccine, Level, IgA level, baseline, lactating, 【제목키워드】 IgG, Vaccine, vaccination, human milk, IgA, dependent on,